In the rapidly evolving landscape of medical treatments, innovations often surface that possess the potential to fundamentally alter existing paradigms. One such breakthrough is the use of atropine drops in managing child myopia. While atropine, a medication traditionally used to dilate the pupil and treat certain eye conditions, may not seem revolutionary at first glance, its application in myopia control is poised to become a game-changer across Europe, particularly with the strategic involvement of companies like Santen.

Based on our analysis, we estimate the potential market for atropine drops in Europe could reach up to €500 million within the next 5 to 10 years. This projection is grounded in the increasing prevalence of myopia, the demonstrated effectiveness of atropine drops in clinical trials, and the anticipated regulatory approvals and market adoption

The Myopia Epidemic

Myopia, or near-sightedness, is a growing concern worldwide, with the World Health Organization (WHO) estimating that half of the global population could be myopic by 2050. Europe is no exception, with a notable increase in the prevalence of myopia among children. Each year, approximately 5 million new cases of myopia are diagnosed in children across Europe, with the average age of diagnosis being around 8 years old. The rising incidence of myopia is alarming, given its association with severe ocular complications later in life, such as retinal detachment, glaucoma, and macular degeneration¹.

Traditionally, myopia management has focused on corrective measures like glasses and contact lenses. However, these solutions do not address the progression of the condition.

Enter atropine drops, an intervention that not only corrects but also slows the progression of myopia.

How Atropine Drops Work